Status:
RECRUITING
Oxytocin Bolus Versus Infusion in Elective Cesarean Section"
Lead Sponsor:
Stony Brook University
Conditions:
Elective Cesarean Section
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
Bolus administration of oxytocin is superior to infusion in time to achieving adequate uterine tone.
Detailed Description
Oxytocin is the most commonly used uterotonic agent worldwide to achieve adequate uterine tone and prevent postpartum hemorrhage. Over the past decade, the trend has been towards lowering the dose to ...
Eligibility Criteria
Inclusion
- Parturients between the ages of 18 to 45 with singleton pregnancies
- Undergoing elective cesarean section under spinal anesthesia
- American Society of Anesthesia (ASA) physical status class I or II
- Patients must be able to provide written informed consent
Exclusion
- Parturients in labor or ruptured membranes
- Multiple gestation
- Risk factors predisposing to uterine atony (history of placenta previa, preeclampsia, diabetes mellitus macrosomia, hydramnios, bleeding diathesis, uterine fibroids)
- History of uterine atony or postpartum hemorrhage
- History of inherited or acquired coagulation disorders, thrombocytopenia (platelet count \<100), or anemia (hemoglobin \< 8)
- History of allergy to oxytocin
- Patients not alert and orientated to person, place, and date. Patient must have, in the investigator's opinion, the physical and mental capacity to answer survey questions
Key Trial Info
Start Date :
March 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05236985
Start Date
March 15 2022
End Date
December 15 2024
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stony Brook University
Stony Brook, New York, United States, 11794-8167